Nuveen LLC Invests $1.17 Million in Dianthus Therapeutics, Inc. $DNTH

Nuveen LLC purchased a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 64,381 shares of the company's stock, valued at approximately $1,168,000. Nuveen LLC owned about 0.20% of Dianthus Therapeutics at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. MetLife Investment Management LLC raised its holdings in Dianthus Therapeutics by 3.1% in the fourth quarter. MetLife Investment Management LLC now owns 14,372 shares of the company's stock worth $313,000 after purchasing an additional 433 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Dianthus Therapeutics by 1.0% in the 1st quarter. Bank of New York Mellon Corp now owns 73,638 shares of the company's stock valued at $1,336,000 after buying an additional 748 shares during the period. Invesco Ltd. increased its position in shares of Dianthus Therapeutics by 7.4% in the 4th quarter. Invesco Ltd. now owns 11,521 shares of the company's stock valued at $251,000 after buying an additional 790 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Dianthus Therapeutics by 0.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 168,102 shares of the company's stock valued at $3,049,000 after buying an additional 1,081 shares in the last quarter. Finally, Barclays PLC raised its stake in Dianthus Therapeutics by 2.6% during the 4th quarter. Barclays PLC now owns 42,766 shares of the company's stock worth $933,000 after buying an additional 1,082 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have issued reports on DNTH. Wedbush boosted their target price on Dianthus Therapeutics from $34.00 to $42.00 and gave the company an "outperform" rating in a research note on Thursday, August 21st. Robert W. Baird decreased their price objective on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Finally, William Blair started coverage on shares of Dianthus Therapeutics in a report on Wednesday, July 2nd. They issued an "outperform" rating for the company. Seven equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Dianthus Therapeutics has an average rating of "Buy" and a consensus price target of $54.00.

Dianthus Therapeutics Price Performance

NASDAQ:DNTH traded up $0.40 during trading hours on Thursday, reaching $24.66. 348,965 shares of the stock were exchanged, compared to its average volume of 324,383. The stock has a market cap of $793.81 million, a PE ratio of -7.59 and a beta of 1.46. Dianthus Therapeutics, Inc. has a twelve month low of $13.36 and a twelve month high of $32.27. The firm has a 50 day moving average of $20.96 and a 200 day moving average of $20.06.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The business had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.87 million. Equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.